Imviva Biotech has revealed promising new data for its allogeneic CAR-T cell therapies, CTD402 and CTA311, at the 67th American Society of Hematology Annual Meeting. Early clinical findings suggest significant progress toward treating T-cell and B-cell malignancies, as well as severe aplastic anemia, through innovative approaches that may offer enhanced efficacy and widened patient access.